Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality

British Journal of Cancer

Volumn 108, Issue 7, 2013, Pages 1515-1524

  Makubate, B ^a   Donnan, P T ^a   Dewar, J A ^a   Thompson, A M ^a   McCowan, C ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGISTRY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SCOTLAND; SURVIVAL ANALYSIS; TAMOXIFEN;

EID: 84876496508     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.116     Document Type: Article

References (28)

1. Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ (2007) Early discontinuation of tamoxifen. Cancer 109(5): 832-839.
2. Bradburn MJ, Clark TG, Love SB, Altman DG (2003) Survival analysis part II: multivariate data analysis-an introduction to concepts and methods. Br J Cancer 89(3): 431-436. (Pubitemid 37026422)
3. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11(12): 1135-1141.
4. Demissie S, Silliman RA, Lash TL (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19(2): 322-328. (Pubitemid 32112842)
5. Dezentje VO, van Blijderveen NJC, Gelderblom H, Putter H, van Herk-Sukel MPP, Casparie MK, Egberts ACG, Nortier JWR, Guchelaar H-J (2010) Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 28(14): 2423-2429.
6. Early Breast Cancer Trialists' Collaborative Group (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793): 771-784.
7. Hadji P (2010) Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 73(2): 156-166.
8. Hershman D, Shao T, Kushi L, Buono D, Tsai W, Fehrenbacher L, Kwan M, Gomez S, Neugut A (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2): 529-537.
9. Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai W-Y, Fehrenbacher L, Lin Gomez S, Miles S, Neugut AI (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8769 early-stage breast cancer patients. J Clin Oncol 28(27): 4120-4128.
10. Ho PM, Bryson CL, Rumsfeld JS (2009) Medication Adherence. Circulation 119(23): 3028-3035.
11. Ma AMT, Barone J, Wallis AE, Wu NJ, Garcia LB, Estabrook A, Rosenbaum-Smith SM, Tartter PI (2008) Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients. Am J Surg 196(4): 500-504.
12. McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, Fahey TP (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99(11): 1763-1768.
13. McCowan C, Thompson AM (2012) The importance of nonpharmacogenetic factors in endocrine therapy. Pharmacogenomics 13(6): 721-728.
14. Murthy V, Bharia G, Sarin R (2002) Tamoxifen non-compliance: does it matter? Lancet Oncol 3(11): 654. (Pubitemid 35314907)
15. Narod SA (2010) Compliance with tamoxifen in women with breast cancer and a BRCA1 or BRCA2 mutation. J Clin Oncol 28(33): e698-e699.
16. Osterberg L, Blaschke T (2005) Adherence to Medication. N Engl J Med 353(5): 487-497. (Pubitemid 41127293)
17. Owusu C, Buist DS, Field TS, Lash TL, Thwin SS, Geiger AM, Quinn VP, Frost F, Prout M, Yood MU, Wei F, Silliman RA, Owusu C, Buist DSM, Field TS, Lash TL, Thwin SS, Geiger AM, Quinn VP, Frost F, Prout M, Yood MU, Wei F, Silliman RA (2008) Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 26(4): 549-555. (Pubitemid 351264347)
18. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26(4): 556-562. (Pubitemid 351264348)
19. Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21(4): 602-606. (Pubitemid 46621892)
20. Patridge A, Wang P, Winer E, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21(4): 602-606. (Pubitemid 46621892)
21. Ruddy K, Mayer E, Partridge A (2009) Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59(1): 56-66.
22. Scottish Government (2012) Scottish Index of Multiple Deprivation: Scottish Government: Edinburgh.
23. Scottish Intercollegiate Guideline Network Guidelines (2005) Breast Cancer in Women: A National Clinical Guideline. Scottish Intercollegiate Guideline Network: Edinburgh.
24. SPSS Inc. (2008) SPSS Statistics for Windows. Version 17.0. SPSS Inc.: Chicago.
25. van de Velde CJH, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel J-M, Paridaens R, Markopoulos C, Hozumi Y, Hille ETM, Kieback DG, Asmar L, Smeets J, Nortier JWR, Hadji P, Bartlett JMS, Jones SE (2011) Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377(9762): 321-331.
26. van Herk-Sukel M, van de Poll-Franse L, Voogd A, Nieuwenhuijzen G, Coebergh J, Herings R (2010) Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat 122(3): 843-851.
27. Yood MU, Owusu C, Buist DS, Geiger AM, Field TS, Thwin SS, Lash TL, Prout MN, Wei F, Quinn VP, Frost FJ, Silliman RA, Yood MU, Owusu C, Buist DSM, Geiger AM, Field TS, Thwin SS, Lash TL, Prout MN, Wei F, Quinn VP, Frost FJ, Silliman RA (2008) Mortality impact of less-than-standard therapy in older breast cancer patients. J Am Coll Surg 206(1): 66-75. (Pubitemid 350267255)
28. Ziller V, Kalder M, Albert US, Holzhauer W, Ziller M, Wagner U, Hadji P (2009) Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 20(3): 431-436.